Search

AbbVie Inc

Closed

SectorHealthcare

255.5 -1

Overview

Share price change

24h

Current

Min

255.1

Max

256.24

Key metrics

By Trading Economics

Income

2.9B

3.6B

Sales

2B

17B

P/E

Sector Avg

74.723

57.366

EPS

3.65

Dividend yield

2.58

Profit margin

21.283

Employees

57,000

EBITDA

5B

8.7B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+9.64% upside

Dividends

By Acuity

Dividend yield

Sector Avg

2.58%

2.16%

Next Earnings

30 Oct 2026

Next Dividend date

13 Nov 2026

Next Ex Dividend date

14 Oct 2026

Market Stats

By TradingEconomics

Market Cap

14B

467B

Previous open

256.5

Previous close

255.5

News Sentiment

By Acuity

46%

54%

107 / 340 Healthcare

AbbVie Inc Chart

Past performance is not a reliable indicator of future results.

Related News

28 Aug 2026, 20:08 UTC

Social Media
Event

AbbVie shares are lower as the company seeks European approval for SKYRIZI. Rising U.S. Treasury yields amid inflation concerns contribute to market declines.

27 Aug 2026, 23:01 UTC

Event

AbbVie Inc. seeks European approval for SKYRIZI to treat Crohn's disease. Shares are higher in after-hours trading following a recent dip.

26 Aug 2026, 23:02 UTC

AbbVie Inc shares are trading lower in after-market hours, showing volatility after Wednesday's close with no specific news identified to explain the movement.

25 Aug 2026, 20:07 UTC

AbbVie Inc shares are higher, supported by favorable macro conditions and lower Treasury yields. The stock is trading near the upper end of its one-month range.

24 Aug 2026, 19:36 UTC

AbbVie Inc. shares are trading lower today, having reached a session low earlier. The stock remains above its 20-day moving average.

21 Aug 2026, 20:06 UTC

News

AbbVie Inc is set to present new data on its bispecific antibody at the 2026 World Conference on Lung Cancer, boosting investor sentiment. Shares are higher today.

20 Aug 2026, 19:31 UTC

News
Correlated Moves

AbbVie shares are lower today, despite Piper Sandler raising its price target to $303 from $298. The decline aligns with broader sector weakness.

19 Aug 2026, 23:01 UTC

AbbVie Inc. is lower in after-market trading, driven by declines in the Biotechnology sub-sector. Recent sessions had shown upward momentum.

18 Aug 2026, 23:51 UTC

Abbvie Inc shares are trading higher in after-market hours, reflecting resilience amid elevated bond yields and inflation concerns. The stock remains above its 20-day moving average.

17 Aug 2026, 23:51 UTC

AbbVie Inc shares are trading lower in after-market hours amid weak broader market sentiment influenced by geopolitical tensions and rising crude oil prices.

14 Aug 2026, 19:46 UTC

Social Media

AbbVie Inc has begun a Phase 2 trial for ABBV-295, yet shares are lower amid negative market sentiment from a decline in U.S. retail sales.

13 Aug 2026, 23:21 UTC

Abbvie Inc shares are lower in after-market hours, with no specific news identified for the decline. Initial jobless claims rose unexpectedly today.

12 Aug 2026, 20:06 UTC

News
Macro Event

AbbVie Inc. shares are lower today, continuing a decline since Tuesday's close, despite FDA acceptance of a BOTOX Cosmetic application for jawline contouring.

11 Aug 2026, 20:06 UTC

News

AbbVie shares are higher as BNP Paribas raises the price target to $247. Allergan Aesthetics enhances its Partner Privileges program to boost customer engagement.

10 Aug 2026, 23:06 UTC

AbbVie Inc shares are lower in after-market hours amid mixed market sentiment influenced by geopolitical tensions and President Trump's comments on economic pressure.

7 Aug 2026, 23:01 UTC

AbbVie Inc shares are trading lower in after-market hours, with no specific news identified to explain the decline. The stock remains near its one-month low.

6 Aug 2026, 20:06 UTC

Social Media

AbbVie Inc shares are lower as bearish sentiment grows in biotech and pharma sectors, with discussions highlighting potential resistance and negative momentum patterns.

5 Aug 2026, 19:26 UTC

News
Event

AbbVie shares are higher as Canada's Drug Agency recommends UBRELVY for migraine treatment. The company also raised its 2026 revenue outlook to $67.60 billion.

4 Aug 2026, 23:01 UTC

Event

AbbVie Inc shares are higher in after-market hours following a recommendation for UBRELVY® reimbursement by Canada's Drug Agency, enhancing patient accessibility.

3 Aug 2026, 23:06 UTC

News

Canaccord Genuity raised its price target for AbbVie to $290, contributing to a modest increase in shares during after-market hours.

31 Jul 2026, 20:04 UTC

News
Event

AbbVie Inc. lowered its 2026 adjusted earnings guidance, now projecting $13.87 to $14.07 per share, contributing to a decline in its stock price today.

30 Jul 2026, 22:41 UTC

Social Media
Event

AbbVie Inc announced JUVÉDERM® Day for August 19, 2026, boosting shares higher in after-market hours amid strong trading activity.

29 Jul 2026, 23:06 UTC

Event

The European Commission approved RINVOQ® for severe alopecia areata, contributing to higher after-market hours trading for Abbvie Inc. Shares remain above their 20-day moving average.

28 Jul 2026, 23:06 UTC

AbbVie Inc. shares traded higher in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

27 Jul 2026, 19:46 UTC

Social Media

AbbVie Inc. shares are trading lower amid a broader market decline, influenced by falling crude oil prices despite recent social media discussions on its 52-week high.

24 Jul 2026, 23:51 UTC

Social Media

Abbvie shares are trading lower in after-market hours despite a presentation on ABBV-CLS-484, a novel cancer immunotherapy inhibitor.

23 Jul 2026, 10:16 UTC

AbbVie Inc shares are trading lower in pre-market hours, with no specific news identified to explain the movement. The stock remains within its one-month trading range.

22 Jul 2026, 23:06 UTC

AbbVie Inc shares are modestly higher in after-market trading. No specific news was identified to explain the movement, amid broader market volatility.

21 Jul 2026, 19:06 UTC

Abbvie Inc. is higher today, supported by broader market gains and optimism in the semiconductor sector after TSMC's potential price increases by 2027.

20 Jul 2026, 23:01 UTC

AbbVie Inc. shares are lower in after-hours trading following a decline from earlier gains, remaining above the 20-day moving average.

Peer Comparison

Price change

AbbVie Inc Forecast

Price Target

By TipRanks

9.64% upside

12 Months Forecast

Average 280.1 USD  9.64%

High 303 USD

Low 225 USD

Based on 23 Wall Street analysts offering 12 month price targets forAbbVie Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

23 ratings

19

Buy

4

Hold

0

Sell

Sentiment

By Acuity

107 / 340 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
help-icon Live chat